In synopsis, it has been shown that SGLT-2 inhibitors can reduce the urolithiasis frequency over all genders and age groups and they can - lower the oxalate output and the inflammatory pathways in the kidneys with high stone risk. This evidence concerns the gene SLC5A2 and urolithiasis.